In Mary Shelley's novel Frankenstein, the fictional monster was an amalgamation of parts from various corpses; when combined, those parts were supposed to form a beautiful creature. Unfortunately, things didn't work out so well, and Victor Frankenstein created a monster.

Nonetheless, Shelley's novel inspired me to imagine what a biotech Frankenstein's monster would look like. This creature would be composed of the best aspects of all the biotech stocks out there, and when sewn together, it would form the ultimate Frankenstock! (Cue ominous lightning, maniacal laughter, etc.)

Frankenstein's monster was nothing until he was given a brain, so I'll steal the experience and intelligence of Genentech's (NYSE:DNA) management team for my Frankenstock. They've been in the industry for a long time, including a CEO who's been with the company for 25 years, and most of its team members have proven scientific backgrounds. In addition, they have historically been one of the more honest, shareholder-friendly management groups in an industry that sometimes lacks scruples -- particularly in its stock option grants.

The heart of this wild biotech beast obviously needs to work reliably under stressful conditions. I've chosen the ticker of Cephalon (NASDAQ:CEPH), which has dependably grown sales 44% and adjusted earnings 31% this year, despite being under legal attack, overcoming regulatory setbacks, and facing near-term generic competition for one of its lead drugs.

Our mad biotech creature won't intimidate others unless he can tower over them, so I'll extend his reach by stitching on PDL Biopharma's (NASDAQ:PDLI) patent collection. That way, I'll capture royalties on nine marketed humanized monoclonal antibodies, and the potential for royalties on at least 34 more drugs in phase 2 clinical trials or later.

The creature will be useless without muscles, so we'll pump him up with the brawn of Roche's (OTC BB: RHHBY.PK) sales and marketing force, and its $33 billion in 2005 drug sales. Its striated marketing muscle is strong in every part of the world, with North American and European drug sales only accounting for 40% and 32% of its total drug revenues. This way, any drugs that our monster produces will easily overpower the competition.

The innards of our biopharmaceutical freak of nature will come from Exelixis (NASDAQ:EXEL). Its internal development, with nine drug candidates in clinical trials and another nine in the preclinical stage, will be essential for this biotech monster's long life and continued growth.

No biotech colossus will be complete unless it can defend itself, so we'll have to teach it the ways of Merck's (NYSE:MRK) legal team. They'll have loads of experience fighting lawsuits once they finish litigating against the more than 23,000 Vioxx-related suits thus far.

Feel like creating your own biotech monster? It's actually easier to make one than you think. Just head on over to Motley Fool CAPS to build a portfolio of biotech or any other stocks. Then see how your Frankenstock performs against others as well as get to see other people's CAPS creations and learn from the collaborative research of thousands.

Fire? Bad! CAPS? Goooooood.

Merck was a former Motley Fool Income Investor pick, while Exelixis and PDL Biopharma are Motley Fool Rule Breakers picks. Try any of our Foolish newsletters free for 30 days.

Fool contributor Brian Lawler is madly devising a scheme to make this biotech monster come to life. He does not own shares of any company mentioned in this article. The Fool has a disclosure policy .

The Motley Ghoul's Tricks or Treats represents the opinions of each Fool only and should in no way be taken as the opinion of either The Motley Fool, Inc., or any company in question, or as representative of anyone or anything other than that specific Fool's thoughts. So do your homework, and review The Motley Fool's disclosure policy .